Hospital
Singing River Gulfport
Singing River Gulfport was paid $24.98M by Medicaid between Jul 2020 and Dec 2024, across 287 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoSINGING RIVER GULFPORT
GULFPORT, MS 39503
GULFPORT, MS 39503
33aNPI1639797913assigned 07/13/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$24.98M
24GClaims569,047
24DCodes billed287
24AFirst – last monthJul 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#21 of 77
Median peer was paid$8.23M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 42,617 | $1.62M | |
| 2021 | 101,548 | $4.31M | |
| 2022 | 156,222 | $6.12M | |
| 2023 | 133,045 | $6.14M | |
| 2024incomplete | 135,615 | $6.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 38,500 | 30,998 | $5.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 23,282 | 17,994 | $4.22M |
| J9271 | Injection, pembrolizumab, 1 mg | 5.6% | 216 | 153 | $1.39M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 12,592 | 9,502 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.5% | 4,543 | 3,613 | $1.11M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.9% | 10,655 | 9,068 | $718K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.5% | 17,801 | 14,959 | $634K |
| G0378 | Hospital observation service, per hour | 2.4% | 1,396 | 992 | $602K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 3,290 | 2,779 | $600K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 5,562 | 4,017 | $546K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 11,292 | 8,812 | $450K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.5% | 3,379 | 2,255 | $364K |
275 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 10,135 | $352K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 3,788 | $338K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 6,967 | $327K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 9,909 | $303K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 864 | $295K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 5,397 | $283K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 11,865 | $267K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,616 | $222K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13,827 | $214K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 391 | $200K |
| 80053 | Comprehensive metabolic panel | <1% | 30,302 | $183K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,730 | $182K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,747 | $176K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,958 | $172K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,863 | $167K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,337 | $165K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,215 | $150K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,347 | $127K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,033 | $127K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,078 | $117K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,126 | $112K |
| 86900 | <1% | 1,968 | $109K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,872 | $109K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,970 | $108K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,714 | $103K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,405 | $87K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 282 | $86K |
| 72100 | <1% | 1,525 | $76K | |
| 74018 | <1% | 1,498 | $75K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 458 | $73K |
| 73630 | <1% | 1,618 | $73K | |
| 73560 | <1% | 1,776 | $69K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,007 | $68K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,566 | $67K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 824 | $66K |
| 73610 | <1% | 1,299 | $62K | |
| 73130 | <1% | 1,315 | $62K | |
| 83880 | <1% | 3,660 | $61K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,364 | $58K |
| 76801 | <1% | 885 | $58K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 936 | $56K |
| 73030 | <1% | 1,397 | $53K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,667 | $50K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,732 | $47K |
| 87807 | <1% | 4,556 | $47K | |
| 84484 | <1% | 7,562 | $46K | |
| 84703 | <1% | 8,668 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,794 | $43K |
| 86850 | <1% | 1,234 | $43K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,417 | $42K |
| 73110 | <1% | 898 | $41K | |
| 81001 | <1% | 20,576 | $40K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,433 | $38K |
| 87400 | <1% | 2,045 | $38K | |
| 74022 | <1% | 539 | $35K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 250 | $35K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 47 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,393 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,393 | $33K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,761 | $33K |
| 86901 | <1% | 1,970 | $33K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,787 | $32K |
| 85027 | <1% | 8,197 | $31K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 52 | $26K |
| 83690 | <1% | 6,368 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 380 | $25K |
| 84702 | <1% | 2,268 | $23K | |
| 96367 | <1% | 655 | $23K | |
| 87070 | <1% | 3,513 | $22K | |
| 93971 | <1% | 494 | $22K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,956 | $21K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,174 | $21K |
| 72040 | <1% | 518 | $21K | |
| 73502 | <1% | 644 | $20K | |
| 87088 | <1% | 3,771 | $19K | |
| 87040 | <1% | 3,027 | $19K | |
| 80061 | Lipid panel | <1% | 2,409 | $18K |
| 74021 | <1% | 297 | $18K | |
| 20610 | <1% | 220 | $18K | |
| 87186 | <1% | 3,155 | $18K | |
| 88312 | <1% | 679 | $17K | |
| 87077 | <1% | 3,241 | $17K | |
| 97116 | <1% | 677 | $15K | |
| 83605 | <1% | 2,546 | $15K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 14 | $15K |
| 96417 | <1% | 467 | $15K | |
| 96416 | <1% | 99 | $15K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 855 | $14K |
| 92526 | <1% | 205 | $14K | |
| 97533 | <1% | 279 | $14K | |
| 81025 | <1% | 2,427 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,515 | $13K |
| 82550 | <1% | 3,652 | $13K | |
| 12001 | <1% | 129 | $12K | |
| 70486 | <1% | 212 | $12K | |
| 82553 | <1% | 2,329 | $11K | |
| 96415 | <1% | 318 | $11K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 68 | $11K |
| 73590 | <1% | 230 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 467 | $10K |
| 87505 | <1% | 128 | $10K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 514 | $9K |
| 82728 | <1% | 1,164 | $9K | |
| 73070 | <1% | 189 | $8K | |
| 83735 | <1% | 2,614 | $8K | |
| 92523 | <1% | 47 | $8K | |
| 84439 | <1% | 1,363 | $8K | |
| 73090 | <1% | 163 | $7K | |
| 10060 | <1% | 87 | $7K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 12 | $7K |
| 74019 | <1% | 111 | $7K | |
| 88304 | <1% | 201 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 106 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 38 | $7K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 115 | $7K |
| 86140 | <1% | 1,984 | $6K | |
| 85610 | <1% | 2,972 | $6K | |
| 85379 | <1% | 1,077 | $6K | |
| 71250 | <1% | 132 | $6K | |
| 85730 | <1% | 1,982 | $6K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 15 | $6K |
| 73562 | <1% | 129 | $5K | |
| 97161 | <1% | 96 | $5K | |
| 82962 | <1% | 3,033 | $5K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 378 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 18 | $4K |
| 97014 | <1% | 682 | $4K | |
| 85651 | <1% | 1,615 | $4K | |
| 95911 | <1% | 13 | $4K | |
| 12011 | <1% | 32 | $4K | |
| 73221 | <1% | 39 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 258 | $4K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 702 | $3K |
| 97162 | <1% | 63 | $3K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 54 | $3K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 35 | $3K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 44 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 60 | $3K |
| 94060 | <1% | 24 | $3K | |
| 82607 | <1% | 346 | $3K | |
| 86481 | <1% | 53 | $2K | |
| 96523 | <1% | 126 | $2K | |
| 81003 | <1% | 1,806 | $2K | |
| 87075 | <1% | 356 | $2K | |
| 82248 | <1% | 570 | $2K | |
| 82803 | <1% | 145 | $2K | |
| 83540 | <1% | 549 | $2K | |
| 83550 | <1% | 411 | $2K | |
| 85007 | <1% | 768 | $2K | |
| 76536 | <1% | 42 | $2K | |
| 59025 | Fetal non-stress test | <1% | 13 | $2K |
| 82247 | <1% | 451 | $2K | |
| 82570 | <1% | 628 | $2K | |
| 86738 | <1% | 153 | $1K | |
| 82043 | <1% | 484 | $1K | |
| 76641 | <1% | 13 | $1K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 55 | $1K |
| 87205 | <1% | 416 | $1K | |
| 87210 | <1% | 300 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,915 | $1K |
| 83615 | <1% | 267 | $982.25 | |
| 83970 | <1% | 56 | $977.34 | |
| 73140 | <1% | 15 | $895.42 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,951 | $895.39 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 161 | $848.99 |
| 76870 | <1% | 12 | $818.63 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 89 | $813.60 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 165 | $806.67 |
| 72170 | <1% | 12 | $783.80 | |
| 82784 | <1% | 84 | $722.43 | |
| 86803 | <1% | 93 | $718.38 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 181 | $665.28 |
| 83655 | <1% | 64 | $652.99 | |
| 80076 | <1% | 126 | $570.53 | |
| 87209 | <1% | 42 | $551.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,165 | $540.35 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 31 | $533.72 |
| 73060 | <1% | 13 | $510.88 | |
| 71101 | <1% | 14 | $510.86 | |
| 85045 | <1% | 192 | $510.07 | |
| 85018 | <1% | 465 | $500.50 | |
| 84100 | <1% | 168 | $487.16 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13 | $473.70 |
| 80074 | <1% | 13 | $396.25 | |
| 87581 | <1% | 12 | $378.96 | |
| 87486 | <1% | 12 | $378.96 | |
| 87449 | <1% | 59 | $365.93 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 78 | $362.30 |
| 80069 | <1% | 85 | $331.93 | |
| 84550 | <1% | 129 | $320.97 | |
| 86677 | <1% | 29 | $274.56 | |
| 87177 | <1% | 42 | $273.03 | |
| 82746 | <1% | 29 | $264.38 | |
| 96411 | <1% | 14 | $256.47 | |
| 83993 | <1% | 15 | $226.45 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 594 | $218.83 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 647 | $208.65 |
| 82375 | <1% | 31 | $200.50 | |
| 36591 | <1% | 296 | $154.22 | |
| 82810 | <1% | 31 | $150.15 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 60 | $149.24 |
| 82009 | <1% | 53 | $135.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,765 | $134.30 |
| 83050 | <1% | 32 | $133.44 | |
| 86308 | <1% | 46 | $129.61 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 286 | $120.77 |
| 85652 | <1% | 72 | $109.45 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,070 | $106.25 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,367 | $97.70 |
| 86038 | <1% | 12 | $87.92 | |
| 82565 | <1% | 52 | $83.90 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,590 | $71.49 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,982 | $68.27 |
| 82378 | <1% | 17 | $68.24 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 859 | $66.48 |
| A9270 | Non-covered item or service | <1% | 3,391 | $51.38 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 155 | $49.92 |
| 82270 | <1% | 18 | $48.78 | |
| 82150 | <1% | 14 | $47.65 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,242 | $46.06 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 82 | $45.16 |
| 86592 | <1% | 16 | $38.72 | |
| J1456 | Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg | <1% | 22 | $32.76 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 418 | $32.50 |
| 84520 | <1% | 33 | $30.84 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,767 | $30.01 |
| 84156 | <1% | 13 | $28.17 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 947 | $25.38 |
| 84145 | <1% | 521 | $24.28 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 871 | $23.30 |
| 99152 | <1% | 35 | $19.99 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,126 | $15.62 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 791 | $13.10 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 116 | $9.60 |
| 96376 | <1% | 1,936 | $8.50 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 988 | $3.95 |
| 36592 | <1% | 448 | $3.41 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 31 | $3.26 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 146 | $3.22 |
| 94760 | <1% | 111 | $3.10 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 89 | $2.78 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 152 | $2.65 |
| 95874 | <1% | 172 | $2.64 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 34 | $2.58 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 38 | $2.09 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 126 | $1.14 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 38 | $0.83 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 277 | $0.76 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 42 | $0.71 |
| J1815 | Injection, insulin, per 5 units | <1% | 284 | $0.23 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 602 | $0.00 |
| 96368 | 0% | 253 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 594 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 280 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 107 | $0.00 |
| 95886 | 0% | 30 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 88 | $0.00 |
| 86258 | 0% | 25 | $0.00 | |
| 80329 | 0% | 362 | $0.00 | |
| 80320 | 0% | 364 | $0.00 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 121 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 14 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 16 | $0.00 |
| 36416 | 0% | 16 | $0.00 | |
| 86364 | 0% | 28 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 46 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 79 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,269 | $0.00 |
| 90715 | 0% | 323 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 476 | $0.00 |
| 94729 | 0% | 13 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 44 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 163 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCNEIL, JASON (CFO)
Parent organizationSINGING RIVER HEALTH SYSTEM
| Provider | Location | Paid |
|---|---|---|
| Singing River Health System | Pascagoula, MS | $81.31M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.